Sagimet Biosciences

Focus: Sagimet Biosciences is a clinical-stage biotech focused on fatty acid synthase (FAS) inhibitors targeting metabolic diseases, oncology, and infectious diseases. The company operates from San Mateo, CA with a lean pipeline currently in Phase 1–3 development.

Infectious Diseases Oncology Metabolic Diseases

Profile data last refreshed 5h ago · AI intelligence enriched 3w ago

Open Jobs

6-1 this month

Stable — net -1 jobs in 30d

1 added, 2 removed. Backfill posture.

Should You Work at Sagimet Biosciences?

AI assessment

Sagimet is a high-conviction, focused biotech bet on a novel mechanism in hot therapeutic areas—attractive for mission-driven clinical and regulatory talent willing to accept Stage risk for potential upside.

Why Work Here

Lead a focused pipeline with three Phase 3 programs in high-value metabolic disease space (MASH/MASLD) where denifanstat has advanced clinical validation.

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Denifanstat

Healthy

PHASE_1

Clinical Trials (1)

NCT07216313A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Phase 1

Help build intelligence for Sagimet Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Work on a novel, differentiated target (FAS inhibition) with multiple therapeutic area applications spanning oncology (KRAS mutations, castration-resistant prostate cancer) and dermatology (acne).

Join during a critical inflection point: recent analyst upgrades (Barclays, September 2026) and planned Phase 1b acne trial enrollment signal near-term momentum and potential milestone-driven upside.

Watch Out For

Limited hiring footprint (7 open roles, concentrated in clinical operations and regulatory) suggests constrained near-term headcount growth and capital intensity typical of pre-profitability biotech.
Pre-revenue stage with no disclosed funding details or cash position data; financial runway and Series funding timeline are opaque, introducing job security uncertainty.

Generated by Claude from Sagimet Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TVB-3567

Acne

PHASE_1

Clinical Trials (1)

NCT06989840Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Phase 1

TVB-2640

Solid Malignant Tumor

PHASE_1

Clinical Trials (1)

NCT02223247A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Phase 1

TVB-2640

Prostatic Neoplasms, Castration-Resistant

PHASE_1

Clinical Trials (1)

NCT05743621Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1

TVB-2640 - 50 mg

Non-alcoholic Steatohepatitis

PHASE_1

Clinical Trials (1)

NCT05835180A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Phase 1

[14C]-TVB-2640

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05657834Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

Phase 1

3-V Bioscience-2640

Metabolic Syndrome

PHASE_1_2

Clinical Trials (1)

NCT02948569Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Phase 1/2

TVB-2640 25 mg

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

PHASE_2

Clinical Trials (1)

NCT03938246Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Phase 2

TVB-2640

KRAS Gene Mutation

PHASE_2

Clinical Trials (1)

NCT03808558Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Phase 2

TVB-2640

Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

PHASE_2

Clinical Trials (1)

NCT04906421Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Phase 2

denifanstat

MASLD

PHASE_3

Clinical Trials (1)

NCT06692283A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Phase 3

Denifanstat

MASH

PHASE_3

Clinical Trials (2)

NCT06594523A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Phase 3

NCT07863193Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

Phase 3

Interview Prep Quick Facts

Portfolio: 13 clinical trials

Top TAs: Infectious Diseases, Metabolic Diseases, Gastroenterology

Publications: 13 in PubMed

Open Roles: 6 active jobs

Therapeutic Area Focus

5 pipeline

3 pipeline

2 pipeline

2 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Private Funding (SEC Form D)

Jan 2021

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response.

Cancer research

2026

PMID:41661672

Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer.

Neoplasia (New York, N.Y.)

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Sagimet Biosciences

Should You Work at Sagimet Biosciences?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Sagimet Biosciences(10)

Open Jobs (6)

Senior Director, Statistics

Senior Medical Writer

Administrative Assistant

Senior Director, Quality

Senior Medical Director

Vice President, Regulatory and Head of Regulatory Affairs

Hiring Trend

Private Funding (SEC Form D)

Research Publications(10)